Physician profile
Jill Johnsen
NPI 1861578718
$991,128.76
in general payments reported to CMS, 2019-2025
8 companies · $726K in 2025
The $726K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108K · 2021: $104K · 2022: $3,786 · 2023: $16K · 2024: $33K · 2025: $726K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $707K · Travel and Lodging: $38K · Honoraria: $21K · Consulting Fee: $8,550 · Food and Beverage: $827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $707,337.00 |
| Travel and Lodging | $38,207.25 |
| Honoraria | $20,680.00 |
| Consulting Fee | $8,550.00 |
| Food and Beverage | $826.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $779,053.00 | 2019-2025 | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human), Nuwiq |
| Genentech, INC. | $194,400.00 | 2019-2021 | |
| Otsuka Pharmaceutical Co., Ltd. | $8,550.00 | 2023 | |
| Csl Behring | $5,362.50 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $3,375.00 | 2021 | |
| Genzyme Corporation | $191.35 | 2022-2025 | |
| Genentech USA, INC. | $172.21 | 2022 | |
| Novo Nordisk INC | $24.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Johnsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.